|
Androgen receptor activation in HER2-negative breast cancer liver metastases. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Theranostics Health |
Patents, Royalties, Other Intellectual Property - Theranostics Health |
|
|
Employment - Theranostics Health |
|
|
Stock and Other Ownership Interests - Ceres Nanosciences; Theranostics Health |
Research Funding - Ceres Nanosciences |
Patents, Royalties, Other Intellectual Property - NIH/NCI |
|
Ahmad Abdelfattah Al-Hader |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - Ceres Nanosciences; Perthera; Theranostics Health |
Stock and Other Ownership Interests - Ceres Nanosciences; Perthera; Theranostics Health |
Honoraria - Ceres Nanosciences; Novartis; Perthera; Symphony Evolution; Theranostics Health |
Consulting or Advisory Role - Ceres Nanosciences; Novartis; Perthera; Theranostics Health |
Research Funding - Ceres Nanosciences (Inst); GlaxoSmithKline (Inst) |
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty |
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera |
|
|
No Relationships to Disclose |